Przeglad gastroenterologiczny · 2026
The prevalence of exocrine pancreatic insufficiency in diabetes mellitus - a multicentre study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kadaj-Lipka Roland, Wynimko Marta, Borowska Karolina, Franek Edward, Mądro Agnieszka, Skrzydło-Radomańska Barbara, Cichoż-Lach Halina, Włodarczyk Barbara, Małecka-Wojciesko Ewa, Czkwianianc Elżbieta, Adrych Krystian, Głuszek Stanisław, Kozieł Dorota, Rydzewska Grażyna
Аннотация
INTRODUCTION: Faecal elastase-1 (FE-1) measurement is a widely utilised screening tool for exocrine pancreatic insufficiency (PEI).
AIM: The present study aimed to assess the prevalence of PEI in diabetic patients and its relationship with diabetes duration, antidiabetic medication use, body mass index, diabetes type, and comorbidities.
MATERIAL AND METHODS: A retrospective study was conducted that included 519 patients with type 1 and type 2 diabetes from five medical centres in Poland. The ScheBo® Pancreatic Elastase-1 Quick™ test was utilised for the measurement of faecal elastase-1 levels. Patients with a history of alcohol abuse, gastrointestinal surgery, or pancreatic cancer were excluded from the study. The medical records of the patients were analysed to obtain clinical data.
RESULTS: Among the 519 patients (262 women, 257 men; mean age: 67 years), 20.2% had an FE-1 level < 200 µg/g, indicating PEI. A statistically significant (p > 0.05) higher prevalence of PEI was observed in patients with obesity (BMI > 25 kg/m2). However, no statistically significant association was found between FE-1 levels and factors such as diabetes duration, antidiabetic medication use, or metabolic control. PEI is prevalent in diabetic patients, with a prevalence exceeding 20%. The findings of this study support the rationale for screening for FE-1 in diabetes and suggest that enzyme replacement therapy may be a viable treatment option for patients diagnosed with PEI.
CONCLUSIONS: The results of this study imply that PEI is not a late complication of diabetes but may occur independently of disease duration.
AIM: The present study aimed to assess the prevalence of PEI in diabetic patients and its relationship with diabetes duration, antidiabetic medication use, body mass index, diabetes type, and comorbidities.
MATERIAL AND METHODS: A retrospective study was conducted that included 519 patients with type 1 and type 2 diabetes from five medical centres in Poland. The ScheBo® Pancreatic Elastase-1 Quick™ test was utilised for the measurement of faecal elastase-1 levels. Patients with a history of alcohol abuse, gastrointestinal surgery, or pancreatic cancer were excluded from the study. The medical records of the patients were analysed to obtain clinical data.
RESULTS: Among the 519 patients (262 women, 257 men; mean age: 67 years), 20.2% had an FE-1 level < 200 µg/g, indicating PEI. A statistically significant (p > 0.05) higher prevalence of PEI was observed in patients with obesity (BMI > 25 kg/m2). However, no statistically significant association was found between FE-1 levels and factors such as diabetes duration, antidiabetic medication use, or metabolic control. PEI is prevalent in diabetic patients, with a prevalence exceeding 20%. The findings of this study support the rationale for screening for FE-1 in diabetes and suggest that enzyme replacement therapy may be a viable treatment option for patients diagnosed with PEI.
CONCLUSIONS: The results of this study imply that PEI is not a late complication of diabetes but may occur independently of disease duration.